Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Arqule Inc (ARQL)

Arqule Inc (ARQL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,417,460
  • Shares Outstanding, K 120,873
  • Annual Sales, $ 25,760 K
  • Annual Income, $ -15,480 K
  • 60-Month Beta 2.49
  • Price/Sales 469.62
  • Price/Cash Flow N/A
  • Price/Book 15.77
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.34
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 03/05/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.10
  • Number of Estimates 5
  • High Estimate -0.10
  • Low Estimate -0.11
  • Prior Year -0.08
  • Growth Rate Est. (year over year) -25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.93 +0.35%
on 01/02/20
20.42 -2.06%
on 12/19/19
-0.07 (-0.32%)
since 12/13/19
3-Month
6.98 +186.53%
on 11/06/19
20.45 -2.20%
on 12/11/19
+11.36 (+131.62%)
since 10/15/19
52-Week
3.15 +534.92%
on 02/28/19
20.45 -2.20%
on 12/11/19
+16.32 (+443.48%)
since 01/15/19

Most Recent Stories

More News
Cardurion Pharmaceuticals Announces Appointment of Peter Lawrence as President and Chief Executive Officer

Cardurion Pharmaceuticals, Inc. (Cardurion), a Boston-based, clinical-stage biotechnology company focused on discovering and developing next-generation therapeutics for the treatment of heart failure and...

ARQL : 20.00 (+0.15%)
MRK : 82.93 (-0.26%)
Replimune Appoints Dieter Weinand as Chairman and Paolo Pucci to the Board of Directors

Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic(TM) platform, today announced the appointment of Dieter Weinand as Chairman...

ARQL : 20.00 (+0.15%)
MRK : 82.93 (-0.26%)
REPL : 21.36 (+3.49%)
Merck Completes Acquisition of ArQule

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common...

MRK : 82.93 (-0.26%)
ARQL : 20.00 (+0.15%)
Moore Kuehn, PLLC Encourages Investors of KEM, ARQL, THOR, and LOGM to Contact the Firm

Moore Kuehn, PLLC, a securities law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders:

KEM : 27.21 (+0.07%)
ARQL : 20.00 (+0.15%)
MRK : 82.93 (-0.26%)
THOR : 67.99 (unch)
LOGM : 86.04 (unch)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders - INST, THOR, TCBI, ARQL

Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:

INST : 49.00 (+0.43%)
THOR : 67.99 (unch)
TCBI : 29.81 (-0.86%)
ARQL : 20.00 (+0.15%)
THOR, ARQL, TIF, and AMTD SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts

Rigrodsky & Long, P.A. announces that it is investigating:

ARQL : 20.00 (+0.15%)
AMTD : 37.82 (+1.80%)
THOR : 67.99 (unch)
TIF : 115.65 (-0.42%)
Merck Begins Tender Offer to Acquire ArQule

Merck (NYSE: MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of ArQule, Inc. (Nasdaq:...

MRK : 82.93 (-0.26%)
ARQL : 20.00 (+0.15%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders - ARQL, KEM, CBPX, TECD

Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:

ARQL : 20.00 (+0.15%)
KEM : 27.21 (+0.07%)
CBPX : 36.99 (unch)
TECD : 144.90 (+0.20%)
SHAREHOLDER ALERT: WeissLaw LLP Investigates ArQule, Inc.

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of ArQule, Inc. ("ArQule" or the "Company") (NASDAQ: ARQL) in connection with the...

ARQL : 20.00 (+0.15%)
MRK : 82.93 (-0.26%)
Why Biotech ETFs are Surging to New Highs

increasing M&A deals and cutting edge therapies are driving biotech ETFs higher

MRK : 82.93 (-0.26%)
SNY : 50.78 (-0.02%)
NVS : 87.11 (+0.94%)
IBB : 133.47 (+2.13%)
BBC : 38.84 (+2.72%)
SBIO : 40.66 (+2.42%)
XBI : 110.81 (+2.54%)
THOR : 67.99 (unch)
MDCO : 84.90 (-0.07%)
ARQL : 20.00 (+0.15%)
AUPH : 14.25 (+1.50%)
ARKG : 62.35 (+3.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade ARQL with:

Business Summary

ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead clinical-stage...

See More

Key Turning Points

2nd Resistance Point 20.01
1st Resistance Point 20.01
Last Price 20.00
1st Support Level 19.99
2nd Support Level 19.97

See More

52-Week High 20.45
Last Price 20.00
Fibonacci 61.8% 13.84
Fibonacci 50% 11.80
Fibonacci 38.2% 9.76
52-Week Low 3.15

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar